-Reuters
Myriad Genetics And Leading Cancer Center Collaborate To Study The Use Of Minimal Residual Disease Testing In Breast Cancer
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease